Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethacrynic Acid Elimination in NMIBC
NCT02852564Phase 1Completed
- Start
- Aug 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ethacrynic acid in Non-muscle-invasive bladder cancer (NMIBC). Primary endpoints: Urine Concentration - Ethacrynic Acid and its conjugates and Excretion Rates - Ethacrynic Acid and its conjugates. Started Aug 2016; status: completed.
02
Drugs
ethacrynic acid
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02852564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852564.